Careful handling and immediate analysis of blood samples are medical standards. However, in the bustling and stressful environment of an intensive care unit, blood samples might unintentionally undergo rule violations. The novel findings of this study demonstrate that many biomarkers from an arterial blood gas sample are robust against pre-analytical mechanical stress or time delay before analysis.
To that end, we compared the test results of an arterial blood gas analysis (BGA) after immediate analysis with those from the same sample after a combination of a defined time delay and simulated mechanical stress. We deliberately exaggerated both confounding variables (time and mechanical forces) to a level greater than expected under real-life conditions. The rationale for this experimental approach was that biomarkers proving stable against supramaximal scenarios would certainly also remain stable against stressors in everyday circumstances.
In our study, the specifications for technical quality control of the analyzers, in accordance with Rili-Baek, were used to define what would constitute a negligible deviation. Deviations of the measured values that were within the methodological measurement inaccuracy were regarded as clinically equivalent. Therefore, a subjective interpretation of values, prone to bias, was initially unnecessary.
The most common blood gas analysis parameters were included in the dataset. The results are interpreted in three different ways.
1. Dissolved gases undergo relevant diffusion processes across the walls of the sample containers. Based on the partial pressure differences between the blood and room air, a net inflow of oxygen from the room air into the sample and a net outflow of carbon dioxide from the sample into the room air occurs [8/9].
In most cases, the increase in pO2 exceeded the margin specified in Rili–Baek. Substantial oxygen enrichment of the samples (mean + 38 mmHg) without any meaningful relation to the patient's condition was observed. Therefore, an interpretation of the oxygenation performance of the patients was categorically impossible in our test scenario.
For CO2, we observed a slight average increase in the partial pressure in the sample vessel (mean +1.2 mmHg; upper limit of agreement < 4 mmHg). At first glance, this observation appears to contradict the net CO2 loss from the containers we described earlier. However, as a result of the substantial increase in hemoglobin oxygenation in the sample vessel, the CO2 previously bound to hemoglobin was released. This so-called Haldane effect obviously outweighs the diffusion loss during the investigation period, and the sum of these effects results in a slight increase in the pCO2 of the sample [10].
These changes in pCO2 were mostly within a 10% deviation margin that we set suggestively. We believe that such a +/- 10% corridor often is part of clinical decision-making patterns. As a consequence, a discussion is warranted whether the observed moderate changes in pCO2 values should be viewed as numerically different but clinically similar and could therefore be used as an approximation of decarboxylation.
2. Some biomarkers of the erythrocyte metabolism (mean lactate +0.6 mmol/L; mean potassium +0.2 mmol/L) were also subject to changes outside the margin of error specified in the Rili-BAEK. While changes in lactate were far beyond a clinically acceptable margin of error, the majority of potassium measurements lay within the above-mentioned 10% corridor. Hence, we would like to spark a discussion, whether clinicians would still view these changes as an acceptable inaccuracy and should utilize those potassium values for therapeutic decisions.
3. Hemoglobin, creatinine, glucose, and electrolytes that are not closely related to erythrocyte metabolism are within the specified accuracy limits except for a few individual observations. Therefore, the results can be regarded as equivalent, justifying the use of these parameters for clinical decision-making, even after time delay and mechanical disturbance.
In summary, it is impossible to draw a uniform picture regarding the pre-analytical validity of our ill-treated blood samples. A differentiated interpretation of each biomarker based on its biochemical and physicochemical properties is required.
Naturally, our study has some strengths and weaknesses. One strength of our interpretative approach lies in using the purely technically derived error margins of the Rili-Baek as a basis for deciding whether value deviations should be regarded as acceptable or un-acceptable. Parameters that were within this predefined margin of error, even after our intervention, can be regarded as reliable with a high degree of probability and can be used for clinical decision-making.
However, some parameters fell into a gray area outside the interpretation certainty of the Rili-Baek margins but they remained within a clinically justified 10% error corridor. Consequently, the interpretation of these values remains debatable.
One limitation of this study is the incomplete selection of only a few standardized confounding factors. Other environmental factors that were not part of our experimental setup, such as temperature fluctuations and ultraviolet radiation, might also affect the pre-analytical stability of blood samples to an unknown extent.
Finally, it might be possible that the excessive degree of rule violations in sample treatment at the supra-everyday level was responsible for the large deviations in results for some biomarkers. One has to wonder, whether a milder form of treatment (for example, only a 30-min delay, only one drop) might have led to smaller changes, closer to Rili-Baek and thus to results that would have been clearer to interpret.